Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab Mucosal Healing in Crohn's Disease
NCT02425111Phase 3Completed
- Sponsor
- Takeda
- Start
- Mar 2015
- Primary completion
- Jun 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 3 trial of vedolizumab in Crohn's disease, sponsored by Takeda. Started Mar 2015; status: completed.
02
Drugs
vedolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02425111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02425111.